ALPHA TAU MEDICAL LTD

Alpha Tau Medical’s 100% response rate in elderly head‑and‑neck cancer patients shows Alpha DaRT + Keytruda outperforms pembrolizumab alone—boosting survival and investor interest.

Alpha Tau Medical’s breakthrough brain‑tumor therapy and rising Nasdaq share price show why its alpha‑emitter radiation devices are reshaping cancer treatment.

Alpha Tau Medical’s 2026 ASCO data show a 42 % objective response and 65 % 12‑month survival for pancreatic cancer using its alpha‑emitter platform, promising a breakthrough in solid‑tumor therapy.

Alpha Tau Medical Ltd is a leading developer of innovative radiation therapy solutions for solid tumors, offering a targeted approach to cancer treatment and serving a global patient base.

Alpha Tau Medical Ltd. reported a GAAP EPS of -$0.11 for Q1 2025, but remains focused on advancing its cancer treatment technologies and expanding its market presence.